Vertex Pharmaceuticals (VRTX) stock
Health Care · Biotechnology
Vertex Pharmaceuticals (VRTX) is a Biotechnology company in the Health Care sector, headquartered in Boston, Massachusetts. As of October 23, 2026, VRTX closed at $523.93, a market capitalization of $132.80 billion, the 91st largest company in the S&P 500. Over the last twelve months it generated $12.59 billion in revenue (+12% year over year) and $3.80 billion in free cash flow. The stock trades at 29.9x trailing earnings and 25.7x forward earnings.
- 1-year total return: +24.0% (dividends reinvested)
- 5-year return: +23.3% a year
- 52-week range: $403.16 – $560.25
- Gross margin 55.0%, operating margin 38.1%
- FI Handbook report card: B across 10 metrics
- 13th largest of 60 Health Care stocks in the S&P 500
VRTX price chart
1Y price change: +24.0% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| VRTX | +1.5% | +15.6% | +24.0% | +12.5% | +23.3% | +20.6% | +14.4% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1991.
VRTX key statistics
- Market cap
- $132.8B
- #91 in S&P 500
- P/E (TTM)
- 29.9x
- Forward P/E
- 25.7x
- EPS (TTM)
- $17.52
- Revenue (TTM)
- $12.6B
- +13%
- Free cash flow
- $3.8B
- Gross margin
- 55.0%
- Operating margin
- 38.1%
- Return on equity
- 23.5%
- Dividend yield
- None
- 52-week range
- $403.16 – $560.25
- Beta
- 0.28
- Price / sales
- 10.6x
- EV / EBITDA
- 24.9x
- Debt / equity
- 0.10x
- Employees
- 6,400
VRTX report card
BTen fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth12.5%B
- Gross margin55.0%B
- Operating margin38.1%A
- FCF margin30.2%A
- Return on equity23.5%B
- Net debt / EBITDA-1.2xA
- Forward P/E25.7xC
- PEG ratio1.9xC
- Shareholder yield1.5%C
- Share count change / yr-0.4%C
Vertex Pharmaceuticals Incorpor financials
Revenue went from $1.7B in fiscal 2016 to $12.0B in fiscal 2025, growing 24.2% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7B | $2.5B | $3.0B | $4.2B | $6.2B | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| Gross profit | $1.5B | $2.2B | $2.6B | $3.6B | $5.5B | $6.7B | $7.9B | $8.6B | $9.5B | $10.3B |
| Operating income | $9.9M | $123.2M | $635.1M | $1.2B | $2.9B | $2.8B | $4.3B | $3.8B | -$232.9M | $4.2B |
| Net income | -$112.1M | $263.5M | $2.1B | $1.2B | $2.7B | $2.3B | $3.3B | $3.6B | -$535.6M | $4.0B |
| EPS (diluted) | $-0.46 | $1.04 | $8.09 | $4.51 | $10.29 | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 |
| Free cash flow | $179.5M | $745.5M | $1.2B | $1.5B | $3.0B | $2.4B | $3.9B | $3.3B | -$790.3M | $3.2B |
| Buybacks | $0 | $0 | $350.0M | $186.0M | $539.1M | $1.4B | $0 | $427.6M | $1.2B | $2.0B |
| Diluted shares | 244.7M | 253.2M | 259.2M | 260.7M | 263.4M | 259.9M | 259.1M | 260.5M | 257.9M | 258.0M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into VRTX?
A reverse DCF asks what growth the current price requires. With an enterprise value of $126.9B and $3.8B of trailing free cash flow, Vertex Pharmaceuticals Incorpor needs to grow free cash flow about 23.7% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 1.3% a year over the last five years.
P/E ratio history
Current 34.2x vs. median 32.8x (10th–90th percentile 20.9x–281.7x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
VRTX analyst price targets
28 analysts' average 12-month target is $571.46 (+9% vs. $523.93). Targets range from $350.00 to $667.00. 81% rate it a buy.
VRTX earnings
Next report: November 2, 2026. Last quarter's revenue was $3.3B (+12% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 3, 2026 | $4.75 | $4.73 | -0.3% |
| May 4, 2026 | $4.31 | $4.47 | +3.8% |
| Feb 12, 2026 | $5.15 | $5.03 | -2.3% |
| Nov 3, 2025 | $4.58 | $4.80 | +4.9% |
| Aug 4, 2025 | $4.25 | $4.52 | +6.3% |
| May 5, 2025 | $4.29 | $4.06 | -5.4% |
| Feb 10, 2025 | $4.02 | $3.98 | -1.0% |
| Nov 4, 2024 | $4.13 | $4.38 | +6.0% |
Stocks like VRTX
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 AMGN Amgen | -1.79% | +54% | $237.5B | 27.3x | Compare |
 GILD Gilead Sciences | -0.73% | +32% | $193.5B | — | Compare |
 REGN Regeneron Pharmaceuticals | -1.72% | +41% | $82.9B | 19.9x | Compare |
 MRNA Moderna | -1.25% | +662% | $79.9B | — | Compare |
 BIIB Biogen | -1.24% | +67% | $37.0B | 44.5x | Compare |
 INCY Incyte | -1.04% | +30% | $23.5B | 14.7x | Compare |
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
VRTX news
- Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept · Oct 25, 2026
- Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. · Oct 24, 2026
- Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III · Oct 24, 2026
- Vertex Stock Looks Expensive. Does It Get Cheaper Ahead? · Oct 23, 2026
- Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors? · Oct 21, 2026
VRTX stock FAQ
What is VRTX's market cap?
Vertex Pharmaceuticals's market capitalization is $132.80 billion as of October 23, 2026, ranking 91st in the S&P 500.
What is VRTX's P/E ratio?
VRTX trades at a trailing price-to-earnings ratio of 29.9x and a forward P/E of 25.7x. Its median P/E over the period we track is 32.8x.
Does VRTX pay a dividend?
No. Vertex Pharmaceuticals does not currently pay a regular cash dividend.
How much has VRTX stock returned?
Including reinvested dividends, VRTX returned +24.0% over one year, +23.3% a year over five years, +20.6% a year over ten years through October 23, 2026.
Is VRTX stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Vertex Pharmaceuticals must grow free cash flow about 24% a year for the next decade. Its free cash flow grew 1% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the VRTX price target?
28 analysts cover VRTX with an average 12-month price target of $571.46, +9% from the current price. 81% of them rate it a buy.
When does VRTX report earnings?
Vertex Pharmaceuticals is expected to report earnings on November 2, 2026.
How many employees does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has about 6,400 full-time employees, or $2.0 million of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology